Rapid Dose Therapeutics Corp AI Stock Analysis
Want to see TSE:DOSE full AI Analyst Report?
Rapid Dose Therapeutics Corp (DOSE) AI Stock Analysis
Rapid Dose Therapeutics Corp
(CNQX:DOSE)
The overall score of 39 reflects a company in a critical financial state. The most significant factor is the insolvent balance sheet with negative equity, which presents an existential risk. This is compounded by fundamentally unprofitable operations with negative gross margins. While a recent improvement in cash flow is a minor positive, it is insufficient to offset the severe financial distress and weak technical trend.
Rapid Dose Therapeutics Corp (DOSE) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 13.78M
- Dividend Yield
- ―
- Average Volume (3M)
- 30.63K
- Price to Earnings (P/E)
- -4.3
- Beta (1Y)
- 0.60
- Revenue Growth
- -19.31%
- EPS Growth
- 34.45%
- Country
- Canada
- Employees
- 12
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Rapid Dose Therapeutics Corp Business Overview & Revenue Model
Company Description
Rapid Dose Therapeutics Corp., headquartered in Burlington, Canada, is a life sciences enterprise dedicated to developing advanced drug delivery technologies aimed at improving health results and individuals' quality of life. The company's flagship p...
How the Company Makes Money
Rapid Dose Therapeutics primarily makes money by monetizing its QuickStrip drug-delivery technology through commercial and strategic arrangements rather than by operating as a large, fully integrated drug manufacturer. Key revenue sources may include...
Rapid Dose Therapeutics Corp Financial Statement Overview
Summary
The company is in financial distress. The income statement shows deeply negative gross margins (-46.9%) and net margins (-148.3%), the balance sheet is insolvent with negative equity of -$8.2M, and while operating cash flow recently turned positive, it is overshadowed by fundamental unprofitability and existential balance sheet risk.
Income Statement
8Very NegativeBalance Sheet
1Very NegativeCash Flow
45Neutral| Breakdown | TTM | May 2026 | May 2025 | May 2024 | Nov 2022 | Feb 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.12M | 2.77M | 2.09M | 1.02M | 718.30K | 755.20K |
| Gross Profit | -993.18K | -956.89K | 1.18M | 563.41K | 372.40K | 699.85K |
| EBITDA | -1.39M | -1.66M | -3.93M | -3.02M | -2.92M | -987.00K |
| Net Income | -3.14M | -3.39M | -5.40M | -4.31M | -3.81M | -1.80M |
Balance Sheet | ||||||
| Total Assets | 2.93M | 3.28M | 1.63M | 1.89M | 2.25M | 3.83M |
| Cash, Cash Equivalents and Short-Term Investments | 8,625 | 11.55K | 20.72K | 161.06K | 27.59K | 70.26K |
| Total Debt | 5.38M | 5.32M | 2.61M | 2.45M | 1.61M | 2.06M |
| Total Liabilities | 11.12M | 10.46M | 6.84M | 5.04M | 4.92M | 5.41M |
| Stockholders Equity | -8.20M | -7.18M | -5.21M | -3.16M | -2.67M | -1.58M |
Cash Flow | ||||||
| Free Cash Flow | 418.18K | -271.29K | -1.15M | -2.29M | -863.92K | -1.63M |
| Operating Cash Flow | 419.09K | -270.39K | -1.15M | -2.29M | -863.92K | -1.62M |
| Investing Cash Flow | -2.55M | -899 | -5,740 | 0 | 0 | -9,124 |
| Financing Cash Flow | 2.12M | 262.13K | 1.01M | 2.43M | 856.53K | 1.65M |
Rapid Dose Therapeutics Corp Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:DOSE, the sentiment is Neutral. The current price of 0.10 is above the 20-day moving average (MA) of 0.10, below the 50-day MA of 0.10, and below the 200-day MA of 0.11, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 49.84 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:DOSE.
Rapid Dose Therapeutics Corp Peers Comparison
Overall Rating
TSE:BLAB52Neutral
TSE:BCT42Neutral
TSE:TELI41Neutral
TSE:HEM39Underperform- TSE:DOSE39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TSE:BLAB | 52Neutral | CAD 11.36M | 0.76 | 101.66% | ― | ― | ― |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| TSE:BCT | 42Neutral | CAD 42.79M | -0.37 | -170.70% | ― | ― | 87.90% |
| TSE:TELI | 41Neutral | CAD 26.67M | 5.15 | 114.66% | ― | 94.58% | ― |
| TSE:HEM | 39Underperform | CAD 10.57M | -2.02 | 92.37% | ― | ― | 16.04% |
| TSE:DOSE | 39Underperform | CAD 13.78M | -4.25 | 42.51% | ― | -19.31% | 34.45% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:DOSE | Rapid Dose Therapeutics Corp | 0.10 | -0.06 | -37.50% | |
| TSE:BCT | BriaCell Therapeutics | 4.89 | -6.51 | -57.11% | |
| TSE:HEM | Hemostemix Inc | 0.05 | -0.04 | -44.44% | |
| TSE:BLAB | Britannia Life Sciences Inc | 0.07 | -0.02 | -26.32% | |
| TSE:TELI | Telescope Innovations Corp | 0.33 | -0.05 | -14.29% |
Rapid Dose Therapeutics Corp Corporate Events
Rapid Dose Therapeutics Moves to Cut Debt with Share Issuance
PositiveRapid Dose Therapeutics Corp. has agreed with certain creditors to exchange up to 5,000,000 common shares for the cancellation of up to $500,000 in outstanding accounts payable. The shares will be issued at $0.10 each under Canadian Securities Exchan...
Rapid Dose Converts Interest and Director Fees to Equity to Strengthen Balance Sheet
PositiveRapid Dose Therapeutics Corp. will issue 1,092,821 common shares to holders of its amended and restated secured convertible notes as payment for approximately $142,000 in quarterly accrued interest, based on a deemed price of $0.13 per share. This mo...
Rapid Dose Therapeutics Secures Second Patent for QuickStrip Nicotine Oral Film
PositiveRapid Dose Therapeutics and Aavishkar Oral Strips have secured a second Indian patent for their QuickStrip Nicotine oral-film technology, this time covering a monolayer formulation and related manufacturing processes. The new 20-year patent complemen...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 04, 2026